SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 90 filers reported holding SPERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $111,000 | -50.7% | 55,438 | -81.7% | 0.00% | – |
| Q2 2022 | $225,000 | -81.7% | 303,201 | +114.4% | 0.00% | – |
| Q1 2022 | $1,231,000 | -44.5% | 141,426 | +2.0% | 0.00% | – |
| Q4 2021 | $2,219,000 | -12.4% | 138,611 | +0.8% | 0.00% | -100.0% |
| Q3 2021 | $2,532,000 | +33.1% | 137,579 | +1.0% | 0.00% | – |
| Q2 2021 | $1,902,000 | -49.5% | 136,262 | -46.7% | 0.00% | -100.0% |
| Q1 2021 | $3,766,000 | +366.7% | 255,800 | +514.6% | 0.00% | – |
| Q4 2020 | $807,000 | +130.6% | 41,621 | +32.7% | 0.00% | – |
| Q3 2020 | $350,000 | -50.2% | 31,365 | -39.6% | 0.00% | – |
| Q2 2020 | $703,000 | +219.5% | 51,958 | +90.6% | 0.00% | – |
| Q1 2020 | $220,000 | -27.4% | 27,262 | -13.6% | 0.00% | – |
| Q4 2019 | $303,000 | +107.5% | 31,546 | +128.5% | 0.00% | – |
| Q3 2019 | $146,000 | -42.3% | 13,806 | -37.2% | 0.00% | – |
| Q2 2019 | $253,000 | +55.2% | 21,977 | +73.2% | 0.00% | – |
| Q1 2019 | $163,000 | +63.0% | 12,692 | -21.6% | 0.00% | – |
| Q4 2018 | $100,000 | – | 16,197 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |